First U.S. Stem Cell Clinical Trial for Pediatric Congenital Heart Disease

Baby with Pediatric Congenital Heart Disease
Pediatric Congenital Heart Disease patient

The Mayo Clinic recently announced the first stem cell based clinical trial for treating pediatric congenital heart disease in the US.  The stem cell therapy seeks to treat hypoplastic left heart syndrome (HLHS), a rare defect in which the left side of the heart is critically underdeveloped.  The treatment utilizes patient’s own [autologous] stem cells taken from the child’s umbilical cord blood.

This trial represents a personalized, stem cell-based therapy that we believe represents  the gold standard in regenerative medicine – using the patient’s own stem cells to treat disease, trauma and injury.

Today, preserving your own stem cells is simple and affordable for families and individuals.   To learn how you can preserve your own valuable stem cells to insure access to emerging personalized regenerative treatments, please visit StemSave or call 877-783-6728 (877-StemSave) today.

To view the full article, click here.

The future of Regenerative Medicine is now™.